RxDoctor Payments Data

Esfandiar Mafi, MD

Family Medicine · Amherst, NYNPI 1780656447

Payments from drug & device makers

$2,771in general payments, 2019–2025

Across 142 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$313
  • GSK$252
  • Takeda Pharmaceuticals U.S.A., Inc.$226
  • Pfizer$185
  • AbbVie$183
  • Regeneron Healthcare Solutions, Inc.$167
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$2,771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,771 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$28,639
Medicare patients
102
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$152,084
JardianceEmpagliflozin109$113,512
TrulicityDulaglutide111$112,137
XareltoRivaroxaban42$50,690
EliquisApixaban37$47,751
MounjaroTirzepatide36$43,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$29,586
FarxigaDapagliflozin Propanediol16$20,224
VascepaIcosapent Ethyl22$16,416
SymbicortBudesonide/Formoterol Fumarate46$14,275
Fluticasone-SalmeterolFluticasone Propion/Salmeterol72$11,014
MyrbetriqMirabegron21$10,852
Metoprolol Succinate340$7,690
Breo ElliptaFluticasone/Vilanterol16$6,530
Praluent PenAlirocumab13$6,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$76$155,234147 claims
Novo NordiskOzempic$105$152,084145 claims
Boehringer IngelheimJardiance$15$113,512109 claims
Johnson & JohnsonXarelto$113$50,69042 claims
PfizerEliquis$185$47,75137 claims
GSKTrelegy Ellipta, Breo Ellipta$252$36,11657 claims
Astellas Pharma US IncMyrbetriq$33$10,85221 claims
AbbVieSynthroid$183$4,45751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →